BI
BIOT.LSE L&G PHARMA BREAKTHROUGH GO UCITS ETF
- USD
No recent price
- Total assets
- -
- Expense ratio
- 0.50%
- Dividend yield
- -
- 1-year return
- +13.27%
- Holdings
- 41
- Since
- 2018
Fund data as reported by the issuer, updated Nov 3, 2026. Total assets are in the fund's base currency.
What does BIOT.LSE invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (65.8%)
- Largest sector: Healthcare (94.3%)
- Largest region: North America (67.8%)
- Top 3 holdings: 9.9% of the fund
Asset allocation
- US stocks 65.8%
- Non-US stocks 34.2%
- Cash 0.1%
Top holdings
- Genmab A/S 4.11%
- Xeris Pharmaceuticals Inc 2.91%
- United Therapeutics Corporation 2.90%
- Halozyme Therapeutics Inc 2.78%
- AstraZeneca PLC 2.77%
L&G PHARMA BREAKTHROUGH GO UCITS ETF performance
Sharpe ratio 0.82- This year
- +9.41%
- 1 year
- +13.27%
- 3 years
- +16.00%
- 5 years
- +2.44%
Volatility 15.8% over 1 year and 14.8% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BIOT.LSE price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
L&G PHARMA BREAKTHROUGH GO UCITS ETF top holdings
28.8% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Genmab A/S GEN.CO | Other | Denmark | 4.11% |
| Xeris Pharmaceuticals Inc XERS.US | Healthcare | United States | 2.91% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 2.90% |
| Halozyme Therapeutics Inc HALO.US | Healthcare | United States | 2.78% |
| AstraZeneca PLC AZN.LSE | Healthcare | United Kingdom | 2.77% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.76% |
| Basilea Pharmaceutica AG BSLN.SW | Healthcare | Switzerland | 2.68% |
| Xencor Inc XNCR.US | Healthcare | United States | 2.67% |
| Ligand Pharmaceuticals Incorporated LGND.US | Healthcare | United States | 2.62% |
| Eisai Co. Ltd. 4523.TSE | Healthcare | Japan | 2.58% |
The 10 largest of 41 holdings.
BIOT.LSE sector exposure
- Healthcare94.3%
- Basic Materials2.1%
Share of the stocks in the fund.
BIOT.LSE regional exposure
- North America67.8%
- Europe Developed16.3%
- Japan10.1%
- United Kingdom3.0%
- Asia Developed2.1%
- Asia Emerging1.8%
Share of the stocks in the fund.
Company size
Average market cap 11.4B- Mega cap5.5%
- Big cap13.8%
- Medium cap30.3%
- Small cap27.8%
- Micro cap21.2%
L&G PHARMA BREAKTHROUGH GO UCITS ETF fund profile
- Fund name
- L&G PHARMA BREAKTHROUGH GO UCITS ETF
- Ticker
- BIOT.LSE
- Exchange
- London Exchange
- Issuer
- LGIM Managers (Europe) Limited
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Inception date
- Jan 18, 2018
- Trading currency
- USD
- Expense ratio
- 0.50%